Previous Close | $1.19 |
AI Value | $44.90 |
Upside potential | +3,673% |
Allogene Therapeutics, Inc. (ALLO) is a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (Chimeric Antigen Receptor T-cell) therapies for cancer. Unlike autologous CAR T therapies, which require patient-specific cell engineering, Allogene’s off-the-shelf approach leverages donor-derived T cells, offering scalability and faster treatment timelines. The company’s lead candidates, ALLO-501 and ALLO-501A, target CD19-positive hematologic malignancies, while ALLO-316 focuses on CD70-expressing solid tumors. Allogene holds a strong position in the emerging allogeneic CAR T space, competing with companies like CRISPR Therapeutics and Precision BioSciences. Its partnership with Pfizer (which contributed assets from its Cellectis collaboration) provides foundational IP and manufacturing expertise.
Proprietary AlloCAR T platform with gene-editing (TALEN®) to reduce graft-vs-host risk. 50+ patents covering cell engineering and manufacturing. Differentiated ‘Dagger’ technology (CD70-targeting) for solid tumors.
Allogene offers high-risk, high-reward exposure to the allogeneic CAR T revolution. Success in Phase 2 trials could validate its platform and attract partnership deals, but clinical setbacks or prolonged FDA scrutiny may pressure shares. Suitable for speculative investors with a 3–5 year horizon. Monitor cash runway and ALLO-316’s solid tumor potential.
Allogene SEC filings (10-K, 10-Q), company presentations, Evaluate Pharma, ClinicalTrials.gov, industry reports (e.g., Nature Reviews Drug Discovery).
Historical valuation data is not available at this time.